News & Updates
Filter by Specialty:
ERAS protocol safe, shortens postoperative stay in elderly gastric cancer patients
Among older adults undergoing gastrectomy for gastric cancer, employing the Enhanced Recovery After Surgery (ERAS) protocol leads to a shorter postoperative hospital stay without introducing new safety signals, a recent study has found.
ERAS protocol safe, shortens postoperative stay in elderly gastric cancer patients
08 Oct 2022Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
07 Oct 2022Inflammation ups risk of chemo-induced decline in frailty status in older women with breast cancer
Robust older women with early breast cancer who have high prechemotherapy levels of both interleukin-6 (IL-6) and C-reactive protein (CRP) are >3 times more likely to experience chemotherapy-induced decline in frailty status than their counterparts with low levels of these inflammatory markers, a prospective study has shown.
Inflammation ups risk of chemo-induced decline in frailty status in older women with breast cancer
05 Oct 2022Quick progression to castration resistance tied to survival in nonmetastatic CRPC
In men with nonmetastatic castration-resistant prostate cancer (M0CRPC), the prostate-specific antigen (PSA) doubling time and the time to castration resistance (TTCRPC) predict cancer-specific survival (CSS), a recent study has found.
Quick progression to castration resistance tied to survival in nonmetastatic CRPC
05 Oct 2022Niraparib maintenance boosts PFS in advanced ovarian cancer
Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.
Niraparib maintenance boosts PFS in advanced ovarian cancer
05 Oct 2022POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).